Action of a Novel PDE4 inhibitor ZL-n-91 on lipopolysaccharide-induced acute lung injury
- PMID: 20074667
- DOI: 10.1016/j.intimp.2010.01.003
Action of a Novel PDE4 inhibitor ZL-n-91 on lipopolysaccharide-induced acute lung injury
Abstract
In the present study, we investigated the effect of classic PDE4 inhibitor rolipram and novel PDE4 inhibitor ZL-n-91 on LPS-induced acute lung injury (ALI) in mice and its mechanism. ALI was induced in ICR mice by instilling intratracheally with LPS, and mice were divided into seven groups: control (Saline), LPS group, ZL-n-91 (3 microg, 10 microg, and 30 microg kg(-1), ip), Rolipram (1.0 mg kg(-1), ip) and dexamethasone (0.5 mg kg(-1), ip). After the 6h of instilling intratracheally with LPS in mice, total leukocyte number, neutrophil number and protein content in BALF increased rapidly, a large number of neutrophil infiltration around the pulmonary vessel and airway, the lung wet weight/dry weight (w/d)ratio raised significantly. MPO activity, TNF-alpha level and cAMP-PDE, PDE4 activity in lung homogenate raised significantly. P(a)O(2), P(a)CO(2) and PH value in peripheral arterial blood also changed obviously, P(a)O(2) and PH value dropped slightly and P(a)CO(2) increased significantly in LPS group. ZL-n-91 (3 microg, 10 microg, 30 microg kg(-1)) dose-dependently reduced the total leukocyte number, neutrophil number and total protein content in BALF, MPO activity, TNF-alpha level and cAMP-PDE, PDE4 activity in lung homogenate, but the effect of ZL-n-91 in pathological changes and lung wet w/d ratio is slight; Rol and Dex significantly reduced lung wet w/d ratio and improved pathological changes, neutrophil around the pulmonary vessel and airway significantly reduced, symptoms of lung edema relieved; The PH value, P(a)O(2) and P(a)CO(2) in ZL-n-91 high dosage group and Rol group had changes, but there was no significant difference compared with LPS group or saline group; After the administration, the righting reflex recovery time significantly shorten in every group of ZL-n-91. the righting reflex recovery time of Rol group was similar with ZL-n-91 30 microg kg(-1) group, while Dex group was similar with saline group. The present study confirms that the inhibitory effect of ZL-n-91(30 microg kg(-1)) on the inflammatory reactivity, including inhibition of inflammatory cell and protein exudation, MPO and PDE4 activity, improvement of the blood gas, those effects were equivalent with rolipram 1 mg kg(-1), and suggested that ZL-n-91 was stronger than rolipram in PDE4 inhibition. So we speculated that ZL-n-91 may have stronger therapeutic potential for treatment of inflammatory disease than rolipram, meantime have stronger nervous system effect than rolipram.
Copyright 2010 Elsevier B.V. All rights reserved.
Similar articles
-
[The effect of recombinant interleukin-10/Fc fusion protein on lipopolysaccharide-induced acute lung injury in mice].Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2008 Aug;20(8):461-4. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2008. PMID: 18687171 Chinese.
-
Zl-n-91, a selective phosphodiesterase 4 inhibitor, suppresses inflammatory response in a COPD-like rat model.Int Immunopharmacol. 2010 Feb;10(2):252-8. doi: 10.1016/j.intimp.2009.11.008. Epub 2009 Nov 13. Int Immunopharmacol. 2010. PMID: 19914404
-
[Protective effect against monoammonium glycyrrhizinate on lipopolysaccharide-induced acute lung injury in mice].Yao Xue Xue Bao. 2007 Sep;42(9):954-8. Yao Xue Xue Bao. 2007. PMID: 18050737 Chinese.
-
Pharmacology of a new cyclic nucleotide phosphodiesterase type 4 inhibitor, V11294.Pulm Pharmacol Ther. 2003;16(2):97-104. doi: 10.1016/S1094-5539(02)00175-X. Pulm Pharmacol Ther. 2003. PMID: 12670778 Review.
-
Selective PDE4 inhibitors as potent anti-inflammatory drugs for the treatment of airway diseases.Mem Inst Oswaldo Cruz. 2005 Mar;100 Suppl 1:131-6. doi: 10.1590/s0074-02762005000900023. Epub 2005 Jun 14. Mem Inst Oswaldo Cruz. 2005. PMID: 15962112 Review.
Cited by
-
ZL-n-91, a specific Phosphodiesterase-4 inhibitor, suppresses the growth of triple-negative breast cancer.Invest New Drugs. 2022 Oct;40(5):875-883. doi: 10.1007/s10637-022-01258-y. Epub 2022 Jun 8. Invest New Drugs. 2022. PMID: 35674866
-
Could cilostazol be beneficial in COVID-19 treatment? Thinking about phosphodiesterase-3 as a therapeutic target.Int Immunopharmacol. 2021 Mar;92:107336. doi: 10.1016/j.intimp.2020.107336. Epub 2020 Dec 28. Int Immunopharmacol. 2021. PMID: 33418248 Free PMC article. Review.
-
The unrecognized effects of phosphodiesterase 4 on epithelial cells in pulmonary inflammation.PLoS One. 2015 Apr 24;10(4):e0121725. doi: 10.1371/journal.pone.0121725. eCollection 2015. PLoS One. 2015. PMID: 25909327 Free PMC article.
-
Anti-inflammatory effects of apigenin in lipopolysaccharide-induced inflammatory in acute lung injury by suppressing COX-2 and NF-kB pathway.Inflammation. 2014 Dec;37(6):2085-90. doi: 10.1007/s10753-014-9942-x. Inflammation. 2014. PMID: 24958013
-
PDE4B Modulates Phosphorylation of p65 (Ser468) via cAMP/PKA in Acute Lung Injury.Lung. 2025 Feb 16;203(1):33. doi: 10.1007/s00408-025-00787-6. Lung. 2025. PMID: 39956855
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous